#United States #Canton #Kelyniam Global #CustomizedBone #Fusion PEEK

Kelyniam Global Announces Strong Q1 2026 Financial Results

Kelyniam Global (OTC: KLYG), renowned for its leadership in custom cranial implants, has recently revealed its financial outcomes for the first quarter ending March 31, 2026. This announcement highlights the company’s impressive revenue growth and a notable increase in profitability, paving the way for a promising financial year ahead.

Financial Highlights

The financial report showcases several key points compared to the same period in 2025:

• - Total Revenue: The company reported total revenues of $1,150,130, marking an astounding 84% increase from $624,910 in the previous year.
• - Gross Profit: An impressive 105% increase in gross profit, with figures rising to $962,814 compared to $470,490.
• - Operating Income: Kelyniam achieved an operating income of $295,295, a significant recovery from an operating loss of $(140,556) recorded in Q1 2025.

These results underscore the dedication of Kelyniam’s team and the escalating demand for its innovative product range. CEO, Ross Bjella, expressed his satisfaction regarding the outcomes, emphasizing the contributions of the team and the robust market interest in their products.

Product Innovations Driving Growth

Sales of Kelyniam’s premier product, the CustomizedBone™ implants, have surged by more than 50% compared to the previous quarter. Licensed from Finceramica, this groundbreaking implant stands out in the market as the only option suitable for children as young as seven years old. Surgeons are increasingly gaining confidence in using these implants, leading to enhanced patient outcomes.

Additionally, Kelyniam witnessed a significant milestone with the successful implantation of the first Fusion PEEK + Bicalcium Phosphate (BCP) implant during the quarter. This innovative technology merges the durability of PEEK with the osteointegration capabilities of BCP, demonstrating Kelyniam's commitment to moving beyond conventional solutions. Both PEEK implants can be delivered overnight and can be equipped with Kelyniam's exclusive integrated fixation system. Notably, Kelyniam retains the exclusive right to market this pioneering product in the United States until March 2028.

Strategic Partnerships

Another factor contributing to this quarter's success includes a consultancy and development agreement signed early in Q1 with a leading medical device firm. This collaboration has generated significant one-time revenue, bolstering the overall financial results for the quarter. Kelyniam is recognized for its solid partnerships within the industry, serving as a reliable ally to medical device companies aiming to penetrate the U.S. cranial market.

About Kelyniam Global

Kelyniam Global specializes in the swift fabrication of custom cranial implants employing advanced computer-aided design and manufacturing technologies. The company is dedicated to producing and distributing cranial and craniofacial implants tailored for the needs of patients undergoing reconstruction. Focused on collaborating with surgeons, health systems, and insurance payors, Kelyniam aims to support successful clinical outcomes while ensuring cost-effective care.

For more information on Kelyniam Global and its product offerings, please visit www.Kelyniam.com.

Looking Forward

As Kelyniam Global moves through 2026, its strong financial start coupled with product innovations and strategic partnerships sets a solid framework for continued success. However, the company also cautions investors, noting that various external factors could impact future performances, a reminder of the inherent risks associated with forward-looking statements as outlined by the Private Securities Litigation Reform Act of 1995.